Report Information More information from: https ://www.wis eguyreports .com/reports /495866
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2016 Report / Search Code: WGR495866
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline Review, H1 2016’, provides an overview of the Ankylos ing Spondylitis (Bekhterev's Dis eas e) pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Ankylos ing Spondylitis (Bekhterev's Dis eas e), complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Ankylos ing Spondylitis (Bekhterev's Dis eas e) and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Ankylos ing Spondylitis (Bekhterev's Dis eas e) - The report reviews pipeline therapeutics for Ankylos ing Spondylitis (Bekhterev's Dis eas e) by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Ankylos ing Spondylitis (Bekhterev's Dis eas e) therapeutics and enlis ts all their major and minor projects - The report as s es s es Ankylos ing Spondylitis (Bekhterev's Dis eas e) therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Ankylos ing Spondylitis (Bekhterev's Dis eas e) Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Identify potential new clients or partners in the target demographic
- Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Ankylos ing Spondylitis (Bekhterev's Dis eas e) pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Ankylos ing Spondylitis (Bekhterev's Dis eas e) Overview 8 Therapeutics Development 9 Pipeline Products for Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Overview 9 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Therapeutics under Development by Companies 10 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Products under Development by Companies 17 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Companies Involved in Therapeutics Development 20 Alteogen Inc. 20 Amgen Inc. 21 BIOCAD 22 Biocon Limited 23 Bionovis SA 24 Boehringer Ingelheim GmbH 25 Brickell Biotech, Inc. 26 Celgene Corporation 27 Celltrion, Inc. 28 Coherus BioSciences , Inc. 29 Epirus Biopharmaceuticals , Inc. 30 Genor BioPharma Co., Ltd. 31 Innovent Biologics , Inc. 32 Johns on & Johns on 33 Lupin Limited 34 Mabion SA 35 Momenta Pharmaceuticals , Inc. 36 Mycenax Biotech Inc. 37 Novartis AG 38 Oncobiologics , Inc. 39 Panacea Biotec Limited 40 Protalix BioTherapeutics , Inc. 41 Sandoz International GmbH 42 Shanghai Pharmaceutical Co., Ltd. 43 Swedis h Orphan Biovitrum AB 44 Therapeutic Proteins International, LLC 45 Vitae Pharmaceuticals , Inc. 46 Xbrane Biopharma AB 47 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Therapeutics As s es s ment 48 As s es s ment by Monotherapy Products 48 As s es s ment by Target 49 As s es s ment by Mechanis m of Action 51 As s es s ment by Route of Adminis tration 53 As s es s ment by Molecule Type 55 Drug Profiles 57 adalimumab bios imilar - Drug Profile 57 adalimumab bios imilar - Drug Profile 58 adalimumab bios imilar - Drug Profile 60 adalimumab bios imilar - Drug Profile 61 adalimumab bios imilar - Drug Profile 62 adalimumab bios imilar - Drug Profile 63 adalimumab bios imilar - Drug Profile 64 adalimumab bios imilar - Drug Profile 65 adalimumab bios imilar - Drug Profile 66 adalimumab bios imilar - Drug Profile 67
adalimumab bios imilar - Drug Profile 68 adalimumab bios imilar - Drug Profile 70 adalimumab bios imilar - Drug Profile 71 adalimumab bios imilar - Drug Profile 72 adalimumab bios imilar - Drug Profile 73 adalimumab bios imilar - Drug Profile 74 anakinra (recombinant) - Drug Profile 75 apremilas t - Drug Profile 77 BBI-6000 - Drug Profile 80 certolizumab pegol bios imilar - Drug Profile 82 COVA-322 - Drug Profile 83 DNX-114 - Drug Profile 84 etanercept bios imilar - Drug Profile 85 etanercept bios imilar - Drug Profile 86 etanercept bios imilar - Drug Profile 87 etanercept bios imilar - Drug Profile 88 etanercept bios imilar - Drug Profile 89 etanercept bios imilar - Drug Profile 90 etanercept bios imilar - Drug Profile 91 etanercept bios imilar - Drug Profile 93 etanercept bios imilar - Drug Profile 94 etanercept bios imilar - Drug Profile 95 golimumab - Drug Profile 96 golimumab bios imilar - Drug Profile 100 golimumab bios imilar - Drug Profile 101 golimumab bios imilar - Drug Profile 102 infliximab bios imilar - Drug Profile 103 infliximab bios imilar - Drug Profile 104 infliximab bios imilar - Drug Profile 105 infliximab bios imilar - Drug Profile 107 infliximab bios imilar - Drug Profile 108 infliximab bios imilar - Drug Profile 109 infliximab bios imilar - Drug Profile 110 infliximab bios imilar - Drug Profile 111 INV-17 - Drug Profile 112 ris ankizumab - Drug Profile 113 s ecukinumab - Drug Profile 115 thalidomide - Drug Profile 121 VTP-43742 - Drug Profile 122 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Recent Pipeline Updates 123 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Dormant Projects 161 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Dis continued Products 163 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Product Development Miles tones 164 Featured News & Pres s Releas es 164 Appendix 173 Methodology 173 Coverage 173 Secondary Res earch 173 Primary Res earch 173 Expert Panel Validation 173 Contact Us 173 Dis claimer 174 Lis t of Tables Number of Products under Development for Ankylos ing Spondylitis (Bekhterev's Dis eas e), H1 2016 13 Number of Products under Development by Companies , H1 2016 15 Number of Products under Development by Companies , H1 2016 (Contd..1) 16 Comparative Analys is by Late Stage Development, H1 2016 17 Comparative Analys is by Clinical Stage Development, H1 2016 18 Comparative Analys is by Early Stage Development, H1 2016 19 Comparative Analys is by Unknown Stage Development, H1 2016 20 Products under Development by Companies , H1 2016 21 Products under Development by Companies , H1 2016 (Contd..1) 22 Products under Development by Companies , H1 2016 (Contd..2) 23 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Alteogen Inc., H1 2016 24 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Amgen Inc., H1 2016 25 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by BIOCAD, H1 2016 26 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Biocon Limited, H1 2016 27 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Bionovis SA, H1 2016 28 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 29 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Brickell Biotech, Inc., H1 2016 30 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Celgene Corporation, H1 2016 31 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Celltrion, Inc., H1 2016 32 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Coherus BioSciences ,
Inc., H1 2016 33 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Epirus Biopharmaceuticals , Inc., H1 2016 34 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 35 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Innovent Biologics , Inc., H1 2016 36 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Johns on & Johns on, H1 2016 37 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Lupin Limited, H1 2016 38 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Mabion SA, H1 2016 39 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Momenta Pharmaceuticals , Inc., H1 2016 40 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Mycenax Biotech Inc., H1 2016 41 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Novartis AG, H1 2016 42 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Oncobiologics , Inc., H1 2016 43 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Panacea Biotec Limited, H1 2016 44 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Protalix BioTherapeutics , Inc., H1 2016 45 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Sandoz International GmbH, H1 2016 46 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 47 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Swedis h Orphan Biovitrum AB, H1 2016 48 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Therapeutic Proteins International, LLC, H1 2016 49 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Vitae Pharmaceuticals , Inc., H1 2016 50 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Pipeline by Xbrane Biopharma AB, H1 2016 51 As s es s ment by Monotherapy Products , H1 2016 52 Number of Products by Stage and Target, H1 2016 54 Number of Products by Stage and Mechanis m of Action, H1 2016 56 Number of Products by Stage and Route of Adminis tration, H1 2016 58 Number of Products by Stage and Molecule Type, H1 2016 60 Ankylos ing Spondylitis (Bekhterev's Dis eas e) Therapeutics - Recent Pipeline Updates , H1 2016 127 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Dormant Projects , H1 2016 165 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Dormant Projects (Contd..1), H1 2016 166 Ankylos ing Spondylitis (Bekhterev's Dis eas e) - Dis continued Products , H1 2016 167 Lis t of Figures Number of Products under Development for Ankylos ing Spondylitis (Bekhterev's Dis eas e), H1 2016 13 Number of Products under Development by Companies , H1 2016 14 Comparative Analys is by Late Stage Development, H1 2016 17 Comparative Analys is by Clinical Stage Development, H1 2016 18 Comparative Analys is by Early Stage Products , H1 2016 19 As s es s ment by Monotherapy Products , H1 2016 52 Number of Products by Targets , H1 2016 53 Number of Products by Stage and Targets , H1 2016 53 Number of Products by Mechanis m of Actions , H1 2016 55 Number of Products by Stage and Mechanis m of Actions , H1 2016 55 Number of Products by Routes of Adminis tration, H1 2016 57 Number of Products by Stage and Routes of Adminis tration, H1 2016 57 Number of Products by Molecule Types , H1 2016 59 Number of Products by Stage and Molecule Types , H1 2016 59
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349